Clinical trial · Interventional
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer
NCT00970580CI-TRIAL-00012078completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BIIB022 With Paclitaxel and Carboplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BIIB022 in Combination with Paclitaxel and Carboplatin
- description
- BIIB022 in Combination with Paclitaxel and Carboplatin
- interventionNames
- Drug: BIIB022 With Paclitaxel and Carboplatin
Primary outcomes (1)
- measure
- To evaluate the safety and tolerability of BIIB022 in combination with paclitaxel and carboplatin
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>/= 18 years old * Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer * ECOG Performance Status 0 or 1 Exclusion Criteria: * History of another primary cancer within 3 years * Any prior or concurrent investigational or standard therapy for treatment of NSCLC * Prior anti-IGF-1R therapy * Unstable diabetes
References
Publications (0)
Data not yet available
No reference posted for this study.